ClinicalTrials.gg
RecruitingNCT06280482Updated Sep 12, 2025

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

A Phase 1 interventional study of Nicotinamide riboside (NR) in Smooth Muscle Dysfunction Syndrome (SMDS), sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by The University of Texas Health Science Center, Houston · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Stroke by The University of Texas Health Science Center, Houston — 6 open to participants now, 9 under way, none of them phase 3. Stroke · The University of Texas Health Science Center, Houston.

Planned enrollment
23rd of 35
15 · median 21
Started
2024
the only one that year
Phase 1
Only one
of the 39
Registered
33rd of 39
by date

Among the 39 studies in Stroke by The University of Texas Health Science Center, Houston, this one is the 23rd largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 1, and was the 33rd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 39 studies in Stroke by The University of Texas Health Science Center, Houston are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Stroke by The University of Texas Health Science Center, Houston, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.

03

Conditions studied

  • Smooth Muscle Dysfunction Syndrome (SMDS)

Keywords

  • smooth muscle aortic alpha-actin (ACTA2)
  • arginine 179 residue
  • Nicotinamide Riboside
  • Stroke
  • Cerebrovascular Disease
  • Thoracic Aortic Aneurysms and Dissections
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals diagnosed with SMDS with confirmed ACTA2 mutation disrupting arginine 179
  • Parental/guardian permission () and, if appropriate, child assent.

Exclusion criteria

Exclusion Criteria:

  • Individuals who have undergone surgery to replace aneurysmal or dissected ascending and root aortic tissue with a graft.
  • Additional medical conditions that impair the patient's ability to participate in the study.
  • Known allergy or sensitivity to niacin or nicotinamide riboside.
  • Prior consumption of niacin or nicotinamide riboside supplement within the prior eight weeks.
  • Failure to provide .
  • Concurrent participation in another intervention trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Treatment

    Drug: Nicotinamide riboside (NR)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in systolic blood

    Time frame: Baseline , 8 weeks

  2. Change in cerebral oxygenation and perfusion as assessed by the Head-up tilt table testing (HUTT) with near-infrared spectroscopy (NIRS) monitoring.

    Time frame: Baseline , 8 weeks

  3. Change in cognitive function as assessed by the NIH Toolbox assessment

    NIH Toolbox assessment evaluates multiple domains of cognitive performance including executive function, attention, episodic memory, language, processing speed, and working memory. Individual test scores are combined into a composite cognition score and reported as age-adjusted T-scores (mean = 50, SD = 10), where higher scores indicate better cognitive function.

    Time frame: Baseline , 8 weeks

  4. Change in autonomic symptoms as assessed by the Composite Autonomic Symptom Score 31 (COMPASS-31) survey

    This is a 31 item questionnaire and each is scored from 0 (no symptoms) to 100(maximum symptom burden), with higher scores indicating more severe autonomic dysfunction.

    Time frame: Baseline , 8 weeks

  5. Change in Impact of headaches as assessed by the Headache Impact Test (HIT-6) questionnaire

    HIT-6 questionnaire consists of 6 questions, each scored from 6(never) to 13(always), with total scores ranging from 36 to 78. Higher scores indicate a greater impact of headaches on quality of life.

    Time frame: Baseline, 8 weeks

  6. Pulmonary function tests (PFTs), including spirometry and lung volume measurements

    Time frame: Baseline, 8 weeks

  7. Change in Aortic diameter as assessed by the echocardiography

    Time frame: Baseline , 8 weeks

Secondary outcomes

  1. Change in Levels of Nicotinamide adenine dinucleotide (NAD+) in whole blood as measured by high-performance liquid chromatography (HPLC)

    Time frame: Baseline , 8 weeks

  2. Change in Levels of NR in whole blood as measured by high-performance liquid chromatography (HPLC)

    Time frame: Baseline , 8 weeks

  3. Safety as assessed by number of participants that show drug toxicity as shown in bloodwork

    Time frame: Baseline

  4. Safety as assessed by number of participants that show drug toxicity as shown in bloodwork

    Time frame: end of study (8 weeks after baseline)

  5. Tolerability as assessed by the number of patients who complete study

    Time frame: end of study( 8 weeks after baseline)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.

Of 71 non-industry phase 1 interventional studies under Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 40 months is above that.

Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Feb 28, 2024
StartActual
Mar 6, 2024
Primary completionEst.
Jul 25, 2027
CompletionEst.
Jul 25, 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06280482
Responsible party
Dianna M Milewicz (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Feb 28, 2024
Start date
Mar 6, 2024
Primary completion
Jul 25, 2027 (estimated)
Completion
Jul 25, 2027 (estimated)
Last update
Sep 12, 2025

Study contacts

Dianna M Milewicz, MD, PhD
Contact
Dianna.M.Milewicz@uth.tmc.edu
(713) 500-6725
David R Murdock, MD
Contact
David.R.Murdock@uth.tmc.edu
(713) 500-6735
Dianna Milewicz, MD, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotinamide-beta-riboside

Start the discussion